Background: Analysis of long-term continuation of biologics in RA is considered a valid surrogate for treatment effectiveness and safety. Only a small number of studies have investigated the long-term persistence with rituximab (RTX) in RA. Methods: This analysis included all patients enrolled with the British Society for Rheumatology Biologics Register for RA when starting RTX between 2008 and 2011. Baseline characteristics (demographic and disease and treatment-related data) were compared between biologicnaive and experienced cohorts. RTX treatment discontinuation was defined as the start of an alternative biologic, death or 1 year following the most recent RTX infusion, whichever came first. Kaplan-Meier curves were used to study discontinuation rates over time and by reason, both as a whole cohort and stratified by past biologic treatment experience; discontinuation rates at 1, 2, 3 and 4 years following treatment initiation were ascertained. The association of baseline variables [age, gender, smoking status, presence of comorbidities, disease duration, 28-joint DAS (DAS28), HAQ score, steroid use, MTX use, previous biologic use] with RTX discontinuation after 4 years was assessed using multivariate Cox proportional hazards models. Results: In total, 1629 patients were included [1371 (84.2%) biologicexperienced patients and 258 (15.8%) biologic-naive patients]. Biologic-experienced patients tended to be younger, but had longer disease duration than biologic-naive patients (Table 1) . Treatment persistence at 4 years was 43% (95% CI 40, 45) and was similar between biologic-naive and biologic-experienced patients (Table 1) . For the whole cohort, baseline variables associated with RTX discontinuation after 4 years were low DAS28 [hazard ratio (HR) 0.91 (95% CI 0.85, 0.98)], RF negativity [HR 0.84 (95% CI 0.72, 0.99)] and younger age [HR 0.99 (95% CI 0.98, 0.99) per year]. A higher number of previously used biologics was associated with RTX discontinuation for the biologic-experienced cohort [HR 1.28 (95% CI 1.08, 1.50)] and smoking history was associated for the biologic-naive cohort only [HR 1.82 (95% CI 1.06, 3.12)]. Tocilizumab was the most commonly used subsequent biologic for both the naive and experienced cohorts: 12 (41.4%) and 133 (56.8%), respectively. Conclusion: Just over half of patients were no longer receiving RTX after 4 years, which was similar in both biologic-naive and experienced patients. In biologic-experienced patients, those who started RTX after two or more past TNFi failures were more likely to discontinue treatment compared with those with only one, which may be identifying a more refractory patient cohort. The role of risk factors in predicting treatment outcomes on RTX is again supported by these data. Disclosure statement: The authors have declared no conflicts of interest.
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